HSP90AA1 and renal cell carcinoma: Here, we report that the pharmacologic inhibition of c-Abl prevents hAha1 interaction with hHsp90α and hypersensitizes renal cell carcinoma (RCC) to Hsp90 inhibitors in vitro and ex vivo.